Dr. Kathleen Neuzil is a professor of medicine and pediatrics and the director of the Center for Vaccine Development and Global Health (CVD) at the University of Maryland School of Medicine. She leads an academic vaccine research and development enterprise that is engaged in the full range of vaccinology – from basic laboratory science research through vaccine development, early clinical evaluation, large-scale prelicensure field studies, and post-licensure assessments. The mission of the CVD is to harness the power of vaccines to prevent disease and save lives, with a focus on the most vulnerable populations. Dr. Neuzil has over two decades of experience in infectious diseases and vaccine science, policy, and introduction. Throughout her career, she has conducted clinical and epidemiologic studies on vaccine-preventable diseases, with an emphasis on viral infections and vaccines – including rotavirus, influenza, respiratory syncytial virus (RSV), Japanese encephalitis virus, and human papillomavirus (HPV). Dr. Neuzil has extensive experience in domestic and international policy, including membership on the Advisory Committee for Immunization Practices (ACIP) of the Centers for Disease Control and Prevention (CDC). She has contributed more than 180 scientific papers on vaccines and infectious diseases. She is currently an associate editor of the journal Vaccine and on the editorial board of npj Vaccines. Dr. Neuzil is also a member of the National Foundation for Infectious Diseases (NFID) Board of Directors and the 2020 Annual Conference on Vaccinology Research Vice Chair. Dr. Neuzil received her undergraduate degree in zoology from the University of Maryland, College Park, her medical degree from the Johns Hopkins University School of Medicine, and her master’s of public health from Vanderbilt University. She received her training in internal medicine and infectious diseases at Vanderbilt University.
Kathleen M. Neuzil, MD, MPH Presentations
June 18, 2020 at 10:00 AM - 11:15 AM
The spread of SARS-CoV-2 and the resulting COVID-19 pandemic has had wide-reaching effects that require a multifaceted response. Accelerating vaccine development and distribution is a key component in responding to this emerging pathogen. Vaccine development typically takes decades from research and development to implementation, so having licensed and approved vaccines available for mass distribution in a 12-18 month timeframe would...
June 19, 2020 at 12:30 PM - 1:45 PM
The late stage development of vaccines for global health use are challenged by complex and costly clinical studies in low-income settings and unclear financial markets. This session will describe the development strategies and partnerships that support the development of malaria, typhoid, and rotavirus vaccines.